Press-release for stocks for adial pharmaceuticals, inc

Prices are updated after-hours

entities : Adial pharmaceuticals, inc crawled time : 14:00

save search

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office
Published: 2024-02-13 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 50.27% | O: 19.33% H: 5.93% C: -8.89%
patent pharmaceuticals

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate
Published: 2023-12-20 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 0.59% | O: 10.65% H: 5.35% C: -7.48%
payment pharmaceuticals

Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th
Published: 2023-03-08 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 283.83% | O: -8.9% H: 27.51% C: 22.92%
pharmaceuticals

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-14 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 509.32% | O: 1.68% H: 3.98% C: -2.33%
pharmaceuticals financial update results

Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5030 as a Potential Treatment for Chronic PainPNV-5030 significantly reduced pain compared to both placebo and acetaminophen
Published: 2022-09-26 (Crawled : 14:00) - biospace.com/
ADIL | News | $1.74 2.35% 130K

Health Technology

| 352.37% | O: -0.35% H: 6.28% C: 3.18%
pnv-5030 treatment pharmaceuticals potential positive

Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use DisorderCompany to host conference call on Wednesday, July 20, 2022, at 1 PM ET
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
ADIL | News | $1.74 2.35% 130K

Health Technology

| 4.29% | O: 6.75% H: 9.2% C: 3.45%
ad04 conference topline trial

Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Published: 2022-07-18 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 4.29% | O: 6.75% H: 9.2% C: 3.45%
ad04 topline trial

Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical TrialExpects Release of Top-Line Data in July
Published: 2022-06-27 (Crawled : 14:00) - biospace.com/
ADIL | News | $1.74 2.35% 130K

Health Technology

| 42.86% | O: 9.24% H: 0.0% C: -5.38%
phase 3 topline

Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Diabetes and NASH
Published: 2022-05-19 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 25.0% | O: 0.74% H: 3.28% C: 0.0%
research collaboration diabetes potential nash

Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Published: 2022-05-16 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| 32.81% | O: 2.73% H: 8.75% C: 7.98%
results

Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors
Published: 2021-11-03 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -46.03% | O: 3.49% H: 0.38% C: -1.23%

Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
Published: 2021-10-18 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -56.19% | O: -1.8% H: 1.57% C: -0.52%
growth conference

Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Published: 2021-09-30 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -59.33% | O: 0.48% H: 3.57% C: 2.14%
alcohol use disorder treatment phase 3 trial

Adial Pharmaceuticals Announces Research Collaboration Agreement with the University of Virginia to Advance Next Generation Adenosine Compounds for Wound Healing
Published: 2021-09-28 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -62.39% | O: -1.11% H: 11.86% C: -4.03%
collaboration research

Sysorex Elects Nasdaq-Listed Company CEO William Stilley to Board of Directors
Published: 2021-09-13 (Crawled : 14:00) - globenewswire.com
AVCO | $0.45 -16.15% 31.11%

Health Technology

| -51.07% | O: -1.04% H: 4.92% C: 2.53%
ADIL | News | $1.74 2.35% 130K

Health Technology

| -58.94% | O: 0.24% H: 0.96% C: -1.69%
ceo nasdaq

Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use Disorder
Published: 2021-08-31 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -58.84% | O: 2.54% H: 3.19% C: -3.19%
alcohol use disorder treatment phase 3 trial enroll

Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive Business Developments
Published: 2021-08-20 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -45.51% | O: 0.32% H: 11.82% C: 6.71%
positive oda conference

Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Using AD04
Published: 2021-08-10 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology

| -37.96% | O: 0.36% H: 6.18% C: -0.73%
treatment opioid patent

Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com
Published: 2021-07-29 (Crawled : 14:00) - globenewswire.com
ADIL | News | $1.74 2.35% 130K

Health Technology